Bempedoic acid

Drug Profile

Bempedoic acid

Alternative Names: ESP-55016; ETC-1002

Latest Information Update: 27 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Esperion Therapeutics
  • Class Antihyperlipidaemics; Antihypertensives; Dicarboxylic acids; Fatty acids; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors; Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypercholesterolaemia
  • Phase II Dyslipidaemias; Hypertension

Most Recent Events

  • 04 May 2017 Esperion plans a phase II trial of Hypercholesterolaemia (Adjunctive treatment to PCSK9i) in 2H 2017
  • 07 Apr 2017 Esperion Therapeutics initiates enrolment in a phase II trial for Hypercholesterolaemia (Adjunctive treatment) in USA (NCT03193047)
  • 20 Mar 2017 Esperion announces intention to submit NDA to US FDA and MAA to the EMA for a cardiovascular indication by 2022 upon successful completion of CLEAR Outcomes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top